5 Key Takeaways
-
1
4D Molecular Therapeutics completed enrollment for the 4FRONT-1 trial of gene therapy 4D-150 in wet age-related macular degeneration.
-
2
The phase 3 trial enrolled treatment-naïve patients at over 100 sites in North America within approximately 11 months.
-
3
4FRONT-1 compares a single injection of 4D-150 with aflibercept administered every 8 weeks, focusing on visual acuity.
-
4
A key secondary endpoint is the reduction in treatment burden, measured by the number of aflibercept injections required.
-
5
Top-line data from the trial are expected in the first half of 2027, with a second phase 3 study, 4FRONT-2, ongoing.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
